$0.3028
0.00662.23%
Últ. Act.: Oct 23, 6:15 PM
Heron Therapeutics (HRTX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Heron Therapeutics (HRTX) publicó su última previsión de mayo 11, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $173M - $183M para el período.
En comparación con la previsión anterior, Heron Therapeutics mantenido redujo su previsión de ingresos desde un rango anterior de $173M - $183M.
Heron Therapeutics ha emitido 16 actualizaciones de orientación entre el noviembre 8, 2022 y el mayo 11, 2026. During this period, the company raised its outlook 3 times and lowered it 5 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.02 | $-0.02 | $-0.03 | $-0.02 |
| Actual | $-0.03 | $-0.04 | $-0.02 | $-0.04 |
| Surprise | -50.0% | -100.0% | +33.3% | -100.0% |
| Revenue | ||||
| Estimate | $42.2M | $36.6M | $39.5M | $38.8M |
| Actual | $37.7M | $34.7M | $40.6M | $38.2M |
| Surprise | -10.8% | -5.16% | +2.67% | -1.63% |
| Metric | Q3 '26E | Q4 '26E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $-0.03 | $-0.03 |
| Revenue | ||
| Consensus | $37.5M | $38.5M |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 10, 2026 | $-0.03 | $-0.02 | -50.0 % |
| Q1 | May 11, 2026 | $-0.04 | $-0.02 | -100.0 % |
| Q4 | Feb 26, 2026 | $-0.02 | $-0.03 | 33.3 % |
| Q3 | Nov 4, 2025 | $-0.04 | $-0.02 | -100.0 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 10, 2026 | $37.67M | $42.24M | -10.8 % |
| Q1 | May 11, 2026 | $34.71M | $36.60M | -5.16 % |
| Q4 | Feb 26, 2026 | $40.59M | $39.53M | 2.67 % |
| Q3 | Nov 4, 2025 | $38.21M | $38.85M | -1.63 % |